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Abstract
Background: Over the last decade, a wide range of attention-deficit/hyperactivity disorder (ADHD) treatment
approaches for adults, including both pharmacological interventions and psychosocial treatments, have been
proposed and observed to be efficient. In practice, individual treatment concepts are based on results of clinical
studies as well as international guidelines (NICE Guidelines) that recommend a step-by-step treatment approach.
Since the evidence supporting this approach is limited, the aim of the present study is to determine an optimal
intervention regarding severity levels of ADHD symptomatology conducting a randomized controlled trial.
Method: We aim to include 279 ADHD subjects aged between 16 and 45 years. First, participants are randomized
to either a face-to-face psychoeducation, telephone assisted self-help (TASH), or a waiting control group (Step 1). All
participants assigned to the control group are treated using TASH after a 3-month waiting period. Participants are
then allocated to one of three groups, based on their remaining severity level of ADHD symptoms, as (1) full
responder, (2) partial responder, or (3) non-responder (Step 2). Full responders receive counseling, partial responders
receive either counseling only or counseling and neurofeedback (NF), and non-responders receive either
pharmacological treatment only or pharmacological treatment and NF, followed by a 3 month period without
intervention.
Discussion: The naturalistic sample is one of the study’s advantages, avoiding highly selective inclusion or
exclusion criteria. The efficacy of an evidence-based stepped care intervention is explored by primary (reduction of
severity of ADHD symptoms) and secondary outcomes (functional outcomes, e.g., quality of life, anger
management, enhancement of psychosocial well-being). Predictors of therapeutic response and non-response are
being investigated at each step of intervention. Further, sex differences are also being explored.
Trial registration: This study is registered by the German Trial Register (reference number: DRKS00008975), 23
October 2015.
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Background
With up to 5.3% of children affected worldwide,
attention-deficit/hyperactivity disorder (ADHD) is one
of the most common diseases with early childhood onset
[1]. ADHD has long been considered a disease of child-
hood, with full remission in adulthood, with adult
ADHD still being questioned by many practitioners.
However, clinical long-term studies have shown that
symptoms fully, or at least partially, persist into adult-
hood in 60% of ADHD patients [2]. Cross-section ana-
lyses support this data. While approximately 3% to 7% of
school-aged children are affected by ADHD [3], preva-
lence in young and middle adulthood, as well as in seni-
ority, ranges between 2% and 5% [1, 4, 5].
Pharmacological treatment
Several meta-analyses provided evidence that short to
medium term pharmacological interventions, using
stimulant medication or atomoxetine as well as psycho-
therapeutic treatment strategies, will improve psycho-
pathological symptoms of adult ADHD [6, 7]. Recent
investigations have revealed smaller effects in psycho-
social interventions than in pharmacological treatment
[6, 7]. However, effect sizes attained by pharmacological
treatments have been found to be smaller for adults than
for adolescents. Additionally, results of pharmacological
trials are generally influenced by study sample selectivity
and pre-defined study approaches, following strict inclu-
sion and exclusion criteria such as comorbidities. There-
fore, the characteristics of patients to be included in the
current study will not necessarily match those of an
average patient with ADHD.
Psychosocial treatment
Regarding low level psychosocial treatment options, psy-
choeducation (PE) is well established in daily practice
[8]. Additionally, telephone assisted self-help (TASH) in-
terventions have been found to be useful for children
and adolescents [9], while they have only been used for
patient parent education. This is a different approach
than in adult psychiatry, where ADHD patients receive
treatment directly. However, knowledge about the effi-
cacy of TASH in adults is limited and promising results
attained by childhood studies cannot yet be transferred
to adult patients. To date, only one randomized con-
trolled pilot study has been published, evaluating an 8-
week bibliotherapy program for adults, in which therap-
ist contact was minimized to phone call sessions. This
study, conducted by Stevenson et al. [10], provides first
promising results suggesting significant improvements of
ADHD symptoms through TASH and the concept dis-
plays high similarities with the program introduced
herein [8].
Neurofeedback (NF) training
Regarding NF training, impaired regulations of slow cor-
tical potentials (SCPs), as well as reduced negativities in
anticipation of tasks, have been observed through elec-
troencephalogram (EEG) recordings for adults and ado-
lescents as compared to children with ADHD. The most
consistent neurophysiological finding in children with
ADHD is an increased absolute power in the theta EEG
band [11–20]; further, several studies have also found
decreased activity in the beta band [19–21]. For adult
ADHD patients, increased absolute power in the alpha
and theta EEG were observed compared to control
groups, while there were no differences in the beta activ-
ity [22, 23]. Thus, the EEG of adult ADHD patients is
characterized by an increased share of slow potentials
and does not show the same abnormality in beta activity
as in children with ADHD [11, 22]. This normalization
of beta activity is associated with a reduced hyperactivity
in adults with ADHD [11, 22].
Strehl et al. [24] investigated the effects of self-
regulation of SCP for children with ADHD. Measure-
ment before and after the trials showed that children
with ADHD are able to learn to regulate negative SCPs.
After training, significant improvement in behavior, at-
tention, and IQ score were observed.
Based on these results, NF trainings were developed to
augment the cortical activation necessary for focused at-
tention and cognitive tasks. In previous research, the use
of SCP as a treatment parameter in NF applications has
been associated with a significant reduction of ADHD
symptoms such as improved attention variables [25] and
corresponding event-related potential (ERP) changes.
EEG recordings during SCP treatment indicated that
children with ADHD were able to control their SCPs
after training, a skill that remained stable after a 2-year
follow-up period. Studies assessing SCP training in adult
patients with ADHD are scarce, but preliminary data
based on 10 adult patients, showed that 15 sessions of
SCP training led to significant improvements regarding
self-ratings of ADHD symptoms. A trend towards
normalization of contingent negative variation ampli-
tudes (CNV; an event-related potential (ERP) related to
aspects of action preparation and self-regulation) could
also be observed [26]. Meta-analytic results, attained by
Sonuga-Barke et al. [27] revealed medium to large ef-
fects (d = 0.59) for children with ADHD, while the ma-
jority of randomized controlled studies (RCTs) included
medicated patients. The authors also report that studies
conducted in a (probably) blinded manner yielded
smaller effects (d = 0.29), reaching only a statistical
trend. Further, they indicated that this estimate may be
too low due to less sensitive ratings and non-
standardized NF [28]. The largest study employing
standard NF and sensitive ratings, as proposed herein,
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reports considerably larger effects (parent rating: d = 0.64,
[25]; teacher rating: d = 0.42, as calculated in [27]). Effect
sizes shown for NF plus medication as compared to
medication alone vary widely, ranging between small
(d = 0.46, [29]) and large effects (d = 2.2, [30, 31]).
Meta-analytic estimates could not be obtained in this
case because many NF RCTs did not exclude patients
with concurrent medication [27]. In conclusion, there
is a wide range of incremental NF effects that cover
potentially large and clinically highly relevant effects.
Until now, only few studies have focused on this
topic, while none of them have included adult sam-
ples. Therefore, the current study aims to investigate
potential effects of NF, along with individual response
predictors, in a stepped care design.
Combined therapy
There is ample evidence surrounding the effects of re-
spective treatment options, yet the number of studies re-
garding combinations of psychosocial intervention and
pharmacological treatment or even the stepped care
model, as suggested here, is very limited. Concerning the
combination of medication and psychosocial treatment
in children and adolescents, the MTA study [32] demon-
strated a superiority of stimulant medication over psy-
chosocial interventions, wherein patients responding to
stimulant treatment did not experience additional bene-
fit when treated with behavior therapy. A recent study of
our consortium compared a structured group program
therapy based on cognitive behavioral therapy (CBT)
and dialectic behavior therapy with individual clinical
management in combination with methylphenidate
(MPH) or placebo in a factorial four condition design
[33]. This study has been granted by the BMBF (Bundes-
ministerium für Bildung und Forschung, Registration:
CCT-ISRCTN54096201). Results suggest that group pro-
gram therapy is not superior compared to clinical man-
agement regarding the primary outcome (ADHD
symptoms after 3 months of intense treatment), whereas
MPH is superior to placebo [34]. Two studies conducted
by Safren et al. [35] and Emilsson et al. [36] employed a
different design, comparing patients treated with ADHD
medication (mostly stimulants) only and patients receiv-
ing medication as well as individual [35] or group [36]
CBT. Both research groups were able to attain a signifi-
cantly more pronounced reduction of ADHD psycho-
pathology for patients through combined treatment.
Study objectives
The limited data regarding combined treatments and the
implementation of a combination of pharmacological
and non-pharmacological treatment options in a stepped
care model are the point of origin of our study concept,
which holds promise for improving the knowledge on
individual treatment optimization for adult ADHD pa-
tients in outpatient facilities. Further, prevailing research
does not yield conclusive results regarding the prediction
of response or non-response to psychosocial or pharma-
cological treatment. The role of psychosocial and bio-
logical predictors such as age, sex, compliance,
comorbidities, lifestyle, adverse environment, or psycho-
social state is yet to be resolved. The majority of studies
concerning predicting factors have used data from
pharmacological trials in an ex-post design to identify
said factors, leading to the assumption that those studies
had primarily been designed to demonstrate pharmaco-
logical efficacy. Since the question of possible differences
concerning therapeutic needs between male and female
patients is almost unmet in relevant research, sex effects
will be of particular interest in the current study. Thus,
we expect to attain new information regarding sex ef-
fects and other confounding variables on treatment ad-
herence and outcome in a sample consisting of adult
ADHD patients.
The paper reports the ESCAlate trial protocol (Evi-
dence-Based, Stepped-Care in Late Adolescents and
Young Adults with Attention-Deficit/Hyperactivity-Dis-
order, Version 05, from December 20, 2016) and has
been conceived under consideration of the SPIRIT
guidelines [37, 38] (Fig. 1 and Additional file 1).
ESCAlife
ESCAlate is part of the research consortium ESCAlife,
whose primary aim is to investigate adaptive interven-
tions for patients with ADHD from preschool age to
adulthood. Besides ESCAlate, ESCAlife encompasses
ESCApreschool for children aged between 3 and 5 years,
ESCAschool for children aged between 6 and 12 years,
and ESCAadol for adolescents aged between 12 and
15 years. Trial protocols of those accompanying studies
are reported elsewhere.
Method
Study conduct and trial flow
The present study is a multisite trial, gathering evidence
via six different recruiting centers adjoined to university
hospitals across Germany (Homburg/Saar, Mainz,
Mannheim, Oldenburg, Rostock, Tübingen). The coord-
inating center is the Institute for Forensic Psychology
and Psychiatry, University of Saarland. To reach a sam-
ple size of N = 279 patients with ADHD, as diagnosed
according to DSM-5 (baseline; T0), we will be able to
mobilize further recruitment centers if needed. Inclusion
criteria are patient age (16–45 years), their or a guard-
ian’s informed consent, and diagnosable ADHD, assessed
through a structured clinical interview (Integrated Diag-
nostic Scale of adult ADHD – Revised; IDA-R) [39–41].
Exclusion criteria consist of IQ < 80 (according to WST
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Fig. 1 Spirit 2013 flow diagram
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[42]), psychiatric disorders (e.g., schizophrenia, acute
psychotic disorders, mania, bipolar disorder, affective
disorders, antisocial personality disorder), and medica-
tion (psychotropic or ADHD). Patients using psycho-
tropic or ADHD medication need to undergo a 4-week
wash-out period before they are eligible for participation
in the study. Further exclusion criteria are current alco-
hol or drug dependence, severe heart disease, epilepsy,
insufficient command of the German language, preg-
nancy, or breast feeding. Common comorbid conditions
such as conduct disorder, personality disorders (except
antisocial personality disorder), anxiety disorder or mild
to moderate depression as well as substance use disorder
in remission do not lead to exclusion.
In a first step (T1), patients will be equally randomized
to the two active treatments or waiting control groups.
One-third of patients will be assigned to face-to-face PE,
which is being implemented through standardized mod-
ules [8]. Eight individual sessions will be administered
with each patient over a period of 3 months. The com-
peting treatment is TASH, which essentially consists of
the same standardized modules as the face-to-face PE,
yet implemented through 30 min telephone sessions.
Those modules include a structured procedure, defining
primary problems that provide specific information con-
cerning ADHD, present coping skills based on CBT, and
require written homework. A third group of patients will
be wait-listed; serving as a control group, these patients
will not receive treatment for 3 months, and will subse-
quently receive TASH. Thus, the duration of step 1 is 3
months for PE and TASH groups and 6 months for the
waiting list control group. We hypothesize that both PE
and TASH will display superior effects in terms of
ADHD symptom reduction as compared to wait-listed
patients after treatment.
Using the IDA-R, treatment response will then be de-
termined (T2). Patients fulfilling our a priori criterion of
full response (IDA-R score ≤ 18) will be followed up by
monthly clinical routine sessions in which they get inter-
viewed by a clinical doctor to control for psychopatho-
logical status and to prevent relapse. During this follow-
up period, no ADHD medication or psychotherapeutic
interventions are allowed. However, in case of relapse or
the emergence of comorbid conditions, all treatment op-
tions fit to improve the patient’s situation are permitted.
Patients categorized as partial responders (IDA-R
score 19–27) will be randomly allocated to either indi-
vidual counseling or individual counseling in combin-
ation with NF, with each intervention being conducted
over a period of 3 months (step 2). As for NF training,
following the standard protocol as proposed by Mayer et
al. [26], SCPs will be recorded at Cz (vertex region), then
referenced against mastoid A1 with a ground electrode
on mastoid A2, and averaged. This will be performed
using NEURO PRAX® (neuroConn group), a full-band
DC-EEG system, primarily intended for neuroscientific
application. For all channels, physiological signals, such
as EEG, electromyogram (EMG), and evoked potentials
(EP), are measured simultaneously and synchronously,
in the frequency range of 0 to 1200 Hz. EEG activities,
from the infra-slow (0 to 0.3 Hz) to the ultra-fast (80 to
1200 Hz), are captured by the unique amplifier technol-
ogy. Various software and hardware modules are able to
make online correction of artifacts caused by muscle
and eye movements, conduct topographical analyses or
spectral and amplitude mapping, as well as online aver-
aging and bio-feedback and NF. Each training session is
composed of four runs of 40 trials, with each trial lasting
8 seconds and consisting of three stages, namely a base-
line phase (0–2 s), an active phase (2–7.5 s), and a
reinforcement phase (7.5–8 s). At the end of the baseline
period, participants will be presented with a cue, namely
a triangle pointed upwards indicating ‘activation’
(regulate a negative SCP shift) or pointed downwards
indicating ‘deactivation’ (regulate a positive SCP shift).
In this active phase, an object moving up or down
across the screen will indicate activation or deactiva-
tion, thus providing feedback to the participant. In a
third phase, participants will be positively reinforced
receiving visual rewards in 75% of cases in which they
successfully directed their SCP activity. In 25% of tri-
als (‘transfer trials’) there will be no feedback, ensur-
ing that the application of regulation does not depend
on the reward system but on acquired skills. The NF
training employed herein comprises 25 sessions in 3
months, with sessions 1–12 being composed of activa-
tion and deactivation trials equally. In sessions 13–25,
the ratio changes to 40% and 60%, respectively. Train-
ing sessions will take place once or twice a week and
last approximately 1 hour each, including preparation
time. Using a waiting list control group or another
passive control group in the second treatment step
can be problematic, as patients not responding suffi-
ciently to therapy in step 1 would be without substan-
tial treatment for 3 months, despite an urgent need
for treatment. In order to avoid this, an individual
counseling program was introduced to the study plan.
Patients randomly assigned to the counseling program
or counseling and NF will receive six individual ses-
sions of 30 min, allowing them to address ADHD-
related symptoms as well as individual, everyday func-
tional problems. The intervention program for coun-
seling in a one-to-one setting is manual-based but not
yet published. It is based on the manual for group
therapy with adult patients with ADHD by D’Amelio
et al. [8]. We hypothesize that NF in combination with
counseling is superior to counseling alone, in reducing
ADHD psychopathology.
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If patients do not respond to treatment obtained in
step 1, they will be considered non-responders (IDA-R
score ≥ 28) and will then be equally randomized to either
a group treated with MPH only or a group treated with
MPH in combination with NF training. MPH has been
chosen as medical treatment because, according to
evidence-based treatment guidelines (NICE Guidelines)
[43], MPH is first line when it comes to ADHD medica-
tion. Medication administration will be coordinated by
each patient’s attending physician as part of their routine
care as recommended by current treatment guidelines
and according to the product information sheet, as well
as the dosage schedule defined by the BfArM (Bundesin-
stitut für Arzneimittel und Medizinprodukte). Specific-
ally, the patients’ medical treatment will begin with a
dosage of 10 mg MPH in the morning and will be in-
creased in steps of 10 mg, with the highest possible dos-
age of 80 mg per day. If significant side effects are
reported, dosage will be again decreased in steps of
10 mg until an appropriate level of medication is found.
The optimal daily dosage will then be maintained and
the number of subdoses taken during the day will be de-
cided individually by the respective medical doctor. A
step-by-step overview of the study process is shown in
Fig. 2. Trial time flow is illustrated in Table 1.
Assessment scope
During step 1, patients will be assessed regarding their
ADHD psychopathology and comorbid conditions at
baseline and in treatment weeks 4, 8, and 12. Patients al-
located to the waiting list group will additionally be eval-
uated at weeks 16, 20, and 24. After the T2 assessment
at the end of step 1, patients who are subsequently being
treated with MPH or a combination of MPH and NF
will be reassessed at T3 regarding their ADHD psycho-
pathology, comorbid conditions, adverse events, and ad-
herence. Patients treated pharmacologically will undergo
safety assessments during step 2 in weeks 13, 14, 15, 16,
Fig. 2 Steps of the ESCAlate treatment program
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18, 20, 22, and 24, while those in the waiting list control
group will undergo each procedure 3 months later. An
identical schedule is being implemented for patients re-
ceiving NF training or NF in combination with individ-
ual counseling.
Psychometric measures and psychophysiological data
Primary outcome
The IDA-R [39–41] is a structured interview assessing
ADHD symptomology and allowing for subtype diagno-
sis following DSM-5 criteria. Essentially, this tool is an
interview version of the ADHD-Diagnosis Checklist
(ADHD-DC) [44], which has been successfully used in
various multicenter studies concerning ADHD (e.g.,
EMMA [45]). Compared to the ADHD-DC, IDA-R
comes with a higher user applicability, as the questions
are already formulated. The examiner estimates the
manifestation of the ADHD pathology based on 18
items. These items are rated on a scale from ‘0’ to ‘3’,
while with a score of ‘2’ the diagnostic criteria of the
DSM-5 is already met (for the specific item). Nine items
are assigned to the inattentive and nine items to the
hyperactive-impulsive type of ADHD. An ADHD diag-
nosis can be made when at least five items are rated with
a score of ‘2’ in one of the two subscales. While there is
no simple cut-off score for diagnosis, the sum score is
only used to differentiate the severity level after the diag-
nosis has already been made. The quality criteria, object-
ivity, reliability, and validity of the IDA-R, based on the
ones of ADHS-DC, are met.
Secondary outcomes
The Clinical Global Impression Scale (CGI) [46] is a sin-
gle question, observer rating scale evaluating the severity
of illness on a 7-point scale. Conducted by clinicians
who are blind to treatment condition, patients are being
assessed judging functional impairment, symptom sever-
ity, and distress or coping. The CGI has been used in
several treatment evaluation studies and has been found
to correlate with ADHD severity measures (e.g., adult
ADHD investigator symptom rating scale [47]).
The Weiss Functional Impairment Rating Scale
(WFIRS-S) [48] is a self-rating scale appraising functional
impairment in seven domains of everyday life (family,
work, school, life skills, self-concept, social, risk). As part
of the recommended diagnostic rating scales provided by
the Canadian Evidence-based and Expert Guidelines, the
WFRIS-S is a widely accepted instrument.
The Wender Reimherr Adult Attention Deficit Dis-
order Scale (WRAADS) [49] is a structured interview
assessing attention deficits, such as motor hyperactivity,
hot temper, affective lability, emotional reactivity,
disorganization, and impulsivity. Its German version rep-
resents one element of the Homburger ADHS Skalen für
Erwachsene [44], where it is originally called the Wender
Reimherr Interview. The WRAADS has been employed
successfully by previous international trials investigating
adult ADHD [49].
The Symptom Checklist-90-Standard (SCL-90-S) [50] is a
self-report symptom inventory and assesses psychopath-
ology of comorbid conditions and subjective distress. Its de-
sign allows for appropriate use in community samples as
well as for medical or psychiatric patients and employs nine
paramount dimensions (somatization, obsessive-compulsive,
interpersonal sensitivity, depression, anxiety, hostility, pho-
bic anxiety, paranoid ideation, psychoticism) and three sum-
mary scores (global score, positive symptom distress index,
and positive symptom total). The SCL-90-S achieves reliabil-
ity indices of α = 0.76–0.98 and has been validated well
through corresponding diagnostic measures [50].
The Adult ADHD Quality of Life Scale (AAQOL-29)
[51] is a 29-item tool developed to assess ADHD-
specific quality of life aspects such as life productivity,
relationships, life outlook, and psychological health. The
AAQOL-29 has been validated using samples from the
United States and Europe and has been implemented by
several clinical trials concerning adult ADHD (e.g., [52]).
The Childhood Trauma Questionnaire (CTQ) [53] is a
five-scale self-report measure, assessing emotional abuse,
physical abuse, sexual abuse, emotional disregard, and
physical disregard. Research shows significant correlations
between childhood trauma and ADHD, using the CTQ to
investigate experiences of victimization [54].
Table 1 ESCAlate timeline flow
1st year 2nd year 3rd year 4th year
Months 1 4 7 10 13 16 19 22 25 28 31 34 37 40 43 47
Preparation (incl. adaptation of treatment manuals,
therapist training, study protocol, electronic case report form)
x x
Initiation of sites x
Recruitment x x x x x x x x
Clinical conduct (treatment and follow-up period) x x x x x x x x x x x x
Database clearing x
Data analysis, publication x
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The Pittsburgh Sleep Quality Index (PSQI) [55] is a self-
assessment questionnaire which surveys sleep quality and
disturbance over the course of 1 month; 19 individual
items aggregate to seven subscales (subjective sleep qual-
ity, sleep latency, sleep duration, habitual sleep efficiency,
sleep disturbance, sleeping medication, daytime dysfunc-
tion) and yield one global score. This measure is being im-
plemented because research shows associations between
adult ADHD and sleep problems [56]. Further, by applying
the PSQI, we will be able to examine if the study’s individ-
ual treatment has improving effects on symptoms of in-
somnia in the course of transfer effects.
The State-Trait Anger Expression Inventory 2 (STAXI-2)
[57] is an assessment tool to evaluate intensity of state
anger, trait anger, anger expression–out, anger expression–
in, anger control–out, anger control–in, and an anger ex-
pression index. Research shows that ADHD is related to
significantly higher levels of state and trait anger [58], which
is why we chose to assess anger management within our
study. Exhibiting good reliability scores and being well vali-
dated through clinical as well as forensic samples, the
STAXI-2 is an internationally employed tool and thus the
measure of choice in this case [59].
The Wortschatztest (WST) [42] is a vocabulary-
based IQ-screening method, enabling rapid assess-
ment of verbal intelligence and appraisal of speech
comprehension. Consisting of 40 tasks arranged in
rows of increasing difficulty, each test task contains
one target word and five distractors. Vocabulary-
based tests like the WST (e.g. STW for English
speaking countries, [60]) have been shown to be use-
ful screening tools, widely used in clinical practice.
This instrument was chosen because it is eligible for
patients from the age of 16, which is crucial in
terms of our objective.
The International Neuropsychiatric Interview Version
6.0 [61] assesses neuropsychiatric symptoms through a
short, structured interview following DSM-IV and
ICD-10 criteria. With an administration time of ap-
proximately 15 min, the International Neuropsychi-
atric Interview Version 6.0 is the instrument of choice
for psychiatric evaluation, as well as outcome tracking
in clinical pharmacological trials and epidemiological
studies. Worldwide, it is the most used psychiatric
structured diagnostic interview, employed by mental
health professionals and health organizations in over
100 countries.
An overview of the psychometric measurements is
given in Table 2.
Psychophysiological data
Using EEG and magnet resonance imaging in the sub-
project ESCAbrain, we aim to obtain potential biological
markers and predictors of ADHD to uncover physical
effects of possible improvements through treatment.
Those assessments will not be administered to all pa-
tients, but only to those subgroups receiving the CBT-
based counseling program and NF or MPH and NF. Pa-
tients will undergo those procedures before they enter
stage 2 of the program and after they have been ran-
domly assigned to subsequent treatment groups.
Using EEG measures, we expect to find predictors of
ADHD within the frequency profile (spontaneous theta
band and alpha band activity) and the intensity of prepara-
tory cognitive activity (CNV amplitude). As suggested by
relevant literature, said indicators represent promising bio-
logical markers of ADHD and explain about 30% of vari-
ability in behavioral improvement following NF treatment
[62]. The magnetic resonance imaging-based predictors
that we hope to identify are part of the fronto-stratial con-
nection (fractional anisotropy) and volumetric grey matter
density of dorsolateral-prefrontal and striatal regions that
have previously been associated with ADHD (e.g., [63]).
To uncover the underlying mechanisms constituting im-
provement through NF training or counseling and pharma-
cological treatment, EEG recordings will be repeatedly
conducted following the second step treatment phase.
Changes in electric brain activity (hypothesized reduction
of resting theta activity and increased CNV activity) will be
treated as additional secondary outcome measures for the
respective subgroups.
All participants and parents/guardians will be in-
formed about the possibility of those additional assess-
ments in advance through general patient information.
Patients assigned to one of the affected groups will add-
itionally be provided with a separate patient information
sheet and asked to give informed consent.
At three points in time during our investigation (T1, T2,
T3), we intend to implement transcranial magnetic stimu-
lation. This method permits a very accurate record of brain
activity, aiming to elucidate processes that could contribute
to problems associated with ADHD. Transcranial magnetic
stimulation will be applied using a Medtronic MagPro
X100 Stimulator with MagOption (Medtronic, Denmark).
A figure-of-eight coil with a diameter of 65 mm will be
placed onto the patient’s head above the supposed hand
area of the motor cortex. Surface electromyography will be
recorded from the contralateral FDI with a standard elec-
tromyographic amplifier (Medtronic Keypoint 4; recording
software: Medtronic Keypoint V 5.01). Filters will be set to
a bandwidth of 1 Hz and 10 kHz, respectively. The optimal
position of the coil will be determined through moving the
coil by 0.5 cm steps until an optimal Motor Evoked Poten-
tials (MEP) can be registered. Resting motor threshold
(RMT) and active motor thresholds will be determined ac-
cording to protocol, as suggested by Kujirai et al. [64].
Further, the Quantified Behavior Test [65] will be
employed. This tool assesses cognitive and behavior
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domains (attention and impulsivity) of adult ADHD
through a continuous performance task, while simultan-
eously recording motor activity using infrared motion
tracking techniques.
Methods against bias
In order to guarantee blinded treatment allocation, an
independent research center, not otherwise engaged in
this investigation, will carry out randomization (Clinical
Trials Unit, University Medical Center Freiburg). Apply-
ing equal allocation ratios to all three conditions at step
1 (step 2), the process will be stratified by the center for
both steps and by partial/non-response criteria in step 2.
Statistical analyses will be conducted using the conserva-
tive intent-to-treat population in order to avoid statis-
tical bias. Corresponding evaluation plans will be
Table 2 Measures
T0 T1 Week 1 T2 Week
12/24 ± 14 days
T3 Week
24/36 ± 14 days
T4 Week
36/48 ± 14 days
Assessment for
eligibility
Study visit:
Baseline
Study visit:
After step 1
Study visit:
After step 2
Study visit:
Follow-up
Screening and inclusion/exclusion criteria X
Informed consent X
Drug screening Xa Xa b b b
Medical history X
Pregnancy test (urine) X Xa c c c
IDA-R Interview X X X X X
CGI X X X X
WRAADS X X X X
IQ (WST) X
M.I.N.I. X
WFIRS X X X X
SCL-90-S X X X X
AAQoL-29 X X X X
CTQ X
PSQI X X X X
STAXI-2 X X X X
QB Test X X X X
TMS X X X X
EEGd X X
Adherence X
List comorbiditye X X X X X
Socioeconomic status X X X X X
Psychopathology and comorbid conditionse in
short study visits during step 1
Week 4 and 8; for waiting list group additionally in week 16 and 20
Psychopathology and comorbid conditionse in
short study visits during step 2
Week 16 and 20; for waiting list group additionally in week 28 and 32
Safety assessmentse during step 2 for
methylphenidate treatment
Week 13, 14, 15, 16, 18, 20 and 22, while waiting list
group will undergo these safety assessments three
months later (week 25, 26, 27, 28, 30, 32 and 34)
Adverse events according psychiatric adverse events (PAEs) Weekly/biweekly between T2 and T3
a According to clinical routine and center standards
bOnly if drug abuse is suspected
cOnly if pregnancy is suspected
dOnly for patients in the NF groups
eA study-specific investigator report, which allows the assessment of neurological as well as psychiatric symptoms
AAQOL-29 Adult ADHD Quality of Life Scale, CGI Clinical Global Impression Scale, CTQ Childhood Trauma Questionnaire, EEG electroencephalogram, IDA-R
Integrated Diagnostic Scale of adult ADHD – Revised, M.I.N.I. 6.0 The International Neuropsychiatric Interview (Version 6), PSQI Pittsburgh Sleep Quality Index, QB
Quantified Behavior Test, SCL-90-S Symptom Checklist-90-Standard, STAXI-2 State-Trait Anger Expression Inventory 2, T test time, TMS transcranial magnetic
stimulation, WFIRS Weiss Functional Impairment Rating Scale, WRAADS Wender Reimherr Adult Attention Deficit Disorder Scale, WST Wortschatztest (vocabulary-
based IQ screening)
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determined prior to analysis. Primary (IDA-R) and sec-
ondary outcomes will be assessed by investigators who are
blind to the patient’s study status. To ensure reliability of
those assessments, investigators will receive appropriate
training prior to study initiation. In addition, supervised
psychosocial treatments are being inaugurated before
launching the study. During PE, two sessions will be
videotaped and evaluated by an independent rater. Using
a structured instrument, the content of each session of PE
as well as counseling will be documented.
Data management
The Clinical Trials Unit of the University Medical Cen-
ter Freiburg will provide electronic questionnaires within
the framework of a remote data entry system (RDE-
LIGHT), while also administering the database. RDE-
LIGHT is a proprietary remote data entry system based
on HTML forms, which is developed, validated, and
maintained by the Clinical Trials Unit of the University
Medical Center Freiburg. Technical specifications of the
trial database, such as variable names and formats, will
be documented in a database manual. Every study center
is asked to carry out the documentation in the electronic
case report form as soon as possible. A user manual for
the RDE-LIGHT system will be provided as this will be
individualized for each study within the ESCALife trial.
Every investigator will be trained in using the documen-
tation system. The data will be reviewed for completion,
consistency, and plausibility using the Statistical Analysis
System (SAS©) software.
Central randomization
Patients fulfilling the eligibility criteria will be random-
ized by the Randomization and Data Management Office
of the Clinical Trials Unit of the Medical Center – Uni-
versity of Freiburg. The randomization procedure has
been described in above. The randomization code will
be produced by validated programs based on the SAS©.
Analysis
Proposed sample size and power calculation
Based on available evidence, sample size was calcu-
lated in order to allow confirmatory evaluation of the
effect of PE versus control (waiting list) at step 1 with
a presumed effect size of 0.45 (change in IDA-R score
from T1 to T2 after intervention/waiting, software:
STPLAN Version 4.3). Conducting a two-sided t test
aiming to reach a power of 80% and a significance
level of 5%, per group, 79 patients are required to
fully pass through study protocol in order to detect a
difference when the true effect size is d = 0.45. With a
1:1:1 allocation ratio for step 1, this yields a power of
24% to detect a difference between TASH and control
when the true effect size is d = 0.2 (exploratory
evaluation of pilot data). To account for the possibil-
ity that some patients (15%) will provide incomplete
data at T2, a total of 279 patients should be random-
ized at step 1. We estimate that approximately 400
patients will have to be screened in order to identify
enough patients suitable for study participation.
Concerning drop-out rates, previous pharmacological
trials with observation periods up to 6 months showed
that premature termination of attendance occurred for
15% of patients within the first 3 months. Another 15%
dropped out within the following 3 months [45, 66].
Therefore, 190 patients will be randomized to the pilot
investigations of NF in step 2, about 47 for each inter-
vention. Based on a conservative estimate of 85% of pa-
tients providing complete data at T3, this yields a power
of 34% to detect an effect of the addition of NF as com-
pared to no NF in partial and non-responders, respect-
ively, when the true effect size is d = 0.3.
Participants will be recruited via outpatient ADHD
centers adjoined to university hospitals and the respect-
ive research institutes involved in the umbrella project
ESCAlife. Patients participating in our routine diagnostic
and treatment program will be screened for eligibility
and recruited accordingly. The average patient flow is
estimated to be between 150 and 300 new ADHD pa-
tients per year and center. Thus, we should be able to
acquire as many patients as needed (N = 279) to achieve
appropriate statistical power. To reach that goal, each
center will need to recruit 25 patients per year, which
seems reasonable and feasible, especially considering the
expertise and experience of the centers involved. For in-
stance, the centers of Freiburg (now Oldenburg, Prof. A.
Philipsen), Würzburg and Homburg/Saar conducted a
multisite ADHD study funded by BMBF (Bundesminis-
terium für Bildung und Forschung, Registration: CCT-
ISTRCTN54096201 and CCT-ISRCTN73911400). The
majority of centers engaged in this study were also in-
volved in large pharmacological trials, e.g., the EMMA
study, with a sample size of N = 359 [45].
An overview of the recruitment numbers is given in
Table 3.
Primary analysis and baseline data
Primary analysis will be conducted according to the
intention-to-treat principle [67]. This means that
data provided by patients will be analyzed according
to the treatment condition to which they were allocated,
irrespective of whether they refused or discontinued treat-
ment or whether other protocol violations were revealed.
The per-protocol (PP) population is a subset of the full
analysis set, defined as the group of patients who had no
major protocol violations, received a predefined minimum
dose of treatment and underwent examinations required
for outcome assessment at relevant, predefined times. To
Zinnow et al. Trials  (2018) 19:280 Page 10 of 15
be included in the PP population, the patients would have
to participate in at least six of eight PE or TASH sessions,
as well as 20 of 25 NF sessions. Sensitivity analysis of said
PP population will be performed [67].
Before including the first patient, a detailed statistical
analysis plan will be prepared and, at the latest, com-
pleted by the time the data is (blindly) reviewed. If the
statistical analysis plan contains any changes to the ana-
lyses outlined in the trial protocol, they will be marked
as such and reasons for amendments will be given.
All statistical programming for analysis will be per-
formed by the SAS®.
Demographic and other baseline characteristics will be
summarized descriptively for all patients.
Continuous data will be summarized by arithmetic
mean, standard deviation, minimum, 25% quantile,
median, 75% quantile, maximum, and the number of
complete and missing observations. If deemed appro-
priate, continuous variables can also be aggregated
into categories.
Categorical data will be summarized with respect to
the total number of patients in each category and the
number of missing values. Relative frequencies are dis-
played as valid percentage (number of patients divided
by the number of patients with non-missing values).
Primary outcomes
Primary statistical analyses of steps 1 and 2 will be con-
ducted by intention to treat, so that all randomized pa-
tients will be analyzed according to their allocated
groups. Changes in the IDA-R score between T1–base-
line and T2 (after interventions/waiting) or T2–baseline
(before randomization to ± NF) and T3, respectively,
will be evaluated in separate mixed-effects models for
repeated measures (MMRM [68]). The MMRMs will in-
clude fixed categorical effects of treatment, center, visit,
and treatment-by-visit interaction as well as continuous
and fixed covariates of baseline and baseline-by-visit
interaction. Further, covariates, which are predictive of
missing values, will be included based on a pre-specified
selection strategy to correct for potential bias arising
from missing data. Unstructured covariance matrices
will be used to model within-patient correlations (a pro-
spective alternative strategy will be devised to address
potential convergence problems). Comparison of pri-
mary treatment change scores at T2 and T3 will be
based on least-squares means with two-sided 95% confi-
dence intervals. Evaluation of PE will be conducted
through confirmatory factor analysis. Subgroup analyses
will be conducted in an exploratory manner by including
interaction terms in the MMRMs, focusing on the ana-
lysis of psychosocial and neurobiological predictors. Par-
ticularly, sex effects will be investigated as prognostic
and predictive factors.
Potential biological predictors are initially assessed
separately for each predictor and treatment through
examination of their correlation with clinical improve-
ment as well as planned comparisons, aiming to identify
age- and treatment-specific predictor patterns. Next,
multivariate pattern classification will be applied, com-
bining markers from different modalities in order to
optimize prediction.
Secondary outcomes
Secondary outcomes will be analyzed descriptively in
a similar fashion as the primary outcome, using re-
gression models as it is appropriate for the respective
type of data. No confirmatory analysis of any of the
secondary outcomes is planned. Treatment effects will
be calculated employing two-sided 95% confidence in-
tervals. Details will be specified in the Statistical Ana-
lysis Plan, which will be prepared before the inclusion
of the first patient.
For all outcome scores (IDA-R, WRAADS, WFIRS-S,
AAQoL-29, PSQI, SCL-90-S, STAXI-2), for changes
from T1 to T2 (intervention groups: after interventions,
control group: after waiting, before TASH) at step 1, and
for changes from T2 (before step 2) to T3 (after inter-
ventions) at step 2, an analysis will be conducted simi-
larly to the primary outcome analysis for continuous
measures. Follow-up assessments of full responders after
step 1 will be evaluated descriptively.
Scores will be calculated according to the respective
manual.
The relationship between childhood trauma (measured
by CTQ) and the severity of ADHD at baseline (defined
by IDA-R) will be analyzed using Spearman correlation
coefficients and linear regression.
Likewise, the relationship between anger management
(measured by STAXI-2) and the severity of ADHD at
baseline (defined by IDA-R) will be analyzed using
Spearman correlation coefficients and linear regression.
Table 3 Patient distribution
Homburg Mainz Oldenburg Tübingen Rostock Mannheim
Number of newly admitted outpatients with ADHD aged 16 years or above n = 200 n = 160 n = 210 n = 200 n = 150 n = 150
To be assessed for eligibility in the 2-year recruitment period (N = 400) n = 100 n = 80 n = 120 n = 100 n = 90 n = 90
To be recruited (N = 300) n = 75 n = 60 n = 80 n = 75 n = 60 n = 60
To be randomized (N = 279) n = 50 n = 40 n = 50 n = 50 n = 50 n = 40
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First, it will be assessed whether anger management is
influenced by allocated therapies (similar to primary out-
come analysis). The relationship between anger manage-
ment at baseline (as measured by STAXI-2) and the
efficiency of the respective treatment, measured by the
difference in severity of ADHD (as defined by IDA-R)
from T0 and T1 and from T2 and T3, will be analyzed
using linear regression.
Missing values
As few patients as possible should discontinue treat-
ment, while all patients who drop out should be
followed up regardless in order to record data as re-
quired by the intention-to-treat principle.
Mean changes from baseline will be analyzed using a
restricted maximum likelihood-based repeated measures
approach. Details will be specified in the Statistical Ana-
lysis Plan.
Quality assurance and monitoring
Monitoring is being performed by the Clinical Trials
Unit of the University Medical Center in Freiburg.
Adapted monitoring will be done according to ICH-
GCP E6 and standard operating procedures. All moni-
toring procedures, such as frequency of visits, and
source data verification will be predefined in the moni-
toring manual. All information recorded on case report
forms must be traceable to source documents in the pa-
tient’s file; the original documents will be kept.
Legal foundation and inclusion of the ethical committee
The study will be conducted in accordance with the
ICH-GCP guidelines and the Declaration of Helsinki.
The study was approved by the local ethic committee.
All substantial changes in the trial protocol or complica-
tions and severe adverse events will be reported to the
ethics committee.
Stopping rules
Key stopping rules for patients are a withdrawal of in-
formed consent or unwillingness to further participate in
the trial or any factors affecting the patient’s well-being.
Key stopping rules for the trial will be if data suggests a
revision of the risk-benefit ratio.
Discussion
Results of our current trial will underpin the recommen-
dations as presented by the evidence-based and expert-
derived treatment guidelines (NICE 2009) with empirical
data. Thus far, evidence for non-pharmacological treat-
ment options in adults with ADHD is limited. From the
view of primary healthcare, predicting ADHD patients’
individual response to relatively low-level psychosocial
interventions (e.g., PE, TASH) or to NF, which are widely
used treatment options in clinical practice, is a pre-
requisite for individualized efficacious therapy in ADHD.
In this regard, we expect that PE and TASH may have
beneficial effects in terms of the adult-specific ADHD
psychopathology and related symptom domains, e.g.,
emotional dysregulation and/or disorganization. If differ-
ences between PE and TASH treatment are found, we
expect them to be very small and thus negligible. More-
over, our study aims to contribute to current research
regarding the potential of NF as a treatment for adults
and late adolescents with ADHD.
There are two aspects to be investigated through
our stepped care program. First, the main question is
whether NF in combination with counselling will dis-
play larger effects than counselling alone. Effects be-
tween d = 0.3 and 0.5 are to be expected. The second
aspect investigated, refers to the effects of NF in
comparison to the well-known effects of MPH treat-
ment. In light of the different modes of action in
both treatments we hypothesize that NF and MPH
might have additive effects and thus a combination
will yield bigger effects as compared to MPH alone.
Another aim of the study is to identify patients who
are in need of pharmacological treatment. In order to
do so, we re-evaluate our patients after they complete
step 1 with respect to therapeutic response and
remaining ADHD psychopathology as measured by
the IDA-R. If a patient scores 18 or lower on the
IDA-R, they will be classified as full responders. An
average item score of this 18-item rating scale of ≤ 1
indicates subclinical presence of ADHD. Non-
response is given if the total score of the IDA-R is ≥
28, corresponding to an average item score of ≥ 1.5.
With reference to our population norms, which have
been acquired within the last decade, a score of 28
has a t value of 81, which is more than two standard
deviations from standard population mean. Partial re-
sponders are defined as patients scoring 19–27 on the
IDA-R, reflecting mild to moderate ADHD. Different
interventions are assigned to full responders, partial
responders, and non-responders. We hypothesize that
symptom severity may be a predictor for the appro-
priateness of different treatment options.
We aim to study different psychosocial and neurobio-
logical predictors of therapeutic response or non-
response. Possible sex effects and the influence of bio-
logical rhythms like sleep patterns are of specific interest
in this context. Additionally, childhood adversity, social
influences, and typical comorbid conditions will be ana-
lyzed regarding treatment outcome at several steps of
treatment. These factors are relevant aspects influencing
the pathogenesis of ADHD but have not yet been inves-
tigated within RCTs concerning late adolescents and
adults.
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Data regarding the effects of different interventions at
different stages of treatment as well as the identification
of possible predictors may open the possibility to
individualize treatment concepts. This may help to im-
plement treatment decisions more effectively and lower
healthcare expenses. Further, identification of optimal,
individualized treatment combinations and concomitant
improvement in terms of psychopathology and func-
tional status will obviously benefit the individual patient.
Another objective of this investigation is the identifica-
tion of typical problems arising when transitioning from
adolescence into adulthood for patients with ADHD.
Thus far, neither adult patients nor adolescents have
been included in treatment studies in order to evaluate
efficacy and tolerability of pharmacological or non-
pharmacological approaches. The age criterion for pa-
tient inclusion in the proposed study is 16 to 45 years,
which closes the gap between adolescence and adult-
hood. Therefore, we have the opportunity to compare
late adolescents with young adults and to study the ef-
fects of different treatments over a life span that is cru-
cial for personal and social development.
Trial status
Protocol version 01 dated 8 July 2015. Latest protocol
version 05 dated 20 December 2016. Date of recruitment
start: 28 January 2016. Date of recruitment end: 31 Oc-
tober 2019.
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